• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估新型酿脓链球菌疫苗候选物,这些候选物包含 M 蛋白 C 重复区的多个保守序列。

Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.

机构信息

Bacterial Pathogenesis Laboratory, The Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia.

出版信息

Vaccine. 2012 Mar 9;30(12):2197-205. doi: 10.1016/j.vaccine.2011.12.115. Epub 2012 Jan 20.

DOI:10.1016/j.vaccine.2011.12.115
PMID:22265945
Abstract

A major challenge for Streptococcus pyogenes vaccine development is the identification of epitopes that confer protection from infection by multiple S. pyogenes M-types. Here we have identified and characterised the distribution of common variant sequences from individual repeat units of the C-repeat region (CRR) of M-proteins representing 77 different M-types. Three polyvalent fusion vaccine candidates (SV1, SV2 and SV3) incorporating the most common variants were subsequently expressed and purified, and demonstrated to be alpha-helical by Circular Dichroism (CD), a secondary conformational characteristic of the CRR in the M-protein. Antibodies raised against each of these constructs recognise M-proteins that vary in their CRR, and bind to the surface of multiple S. pyogenes isolates. Antibodies raised against SV1, containing five variant sequences, also kill heterologous S. pyogenes isolates in in vitro bactericidal assays. Further structural characterisation of this construct demonstrated the conformation of SV1 was stable at different pHs, and thermal unfolding of SV1 is a reversible process. Our findings demonstrate that linkage of multiple variant sequences into a single recombinant construct overcomes the need to embed the variant sequences in foreign helix promoting flanking sequences for conformational stability, and demonstrates the viability of the polyvalent candidates as global S. pyogenes vaccine candidates.

摘要

链球菌疫苗开发的主要挑战是确定能够预防多种 A 群链球菌 M 型感染的表位。在这里,我们鉴定并描述了代表 77 种不同 M 型的 M 蛋白 C 重复区(CRR)的单个重复单元的常见变异序列的分布。随后表达和纯化了包含最常见变异的三种多价融合疫苗候选物(SV1、SV2 和 SV3),并通过圆二色性(CD)证明它们是α-螺旋,这是 M 蛋白 CRR 的二级构象特征。针对这些构建体中的每一个产生的抗体识别在其 CRR 中变化的 M 蛋白,并与多种 A 群链球菌分离株的表面结合。针对包含五个变异序列的 SV1 产生的抗体也能在体外杀菌测定中杀死异源 A 群链球菌分离株。对该构建体的进一步结构表征表明,SV1 的构象在不同 pH 值下稳定,并且 SV1 的热解折叠是一个可逆过程。我们的研究结果表明,将多个变异序列链接到单个重组构建体中克服了将变异序列嵌入促进构象稳定性的外源螺旋促进侧翼序列的需要,并证明了多价候选物作为全球 A 群链球菌疫苗候选物的可行性。

相似文献

1
Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.评估新型酿脓链球菌疫苗候选物,这些候选物包含 M 蛋白 C 重复区的多个保守序列。
Vaccine. 2012 Mar 9;30(12):2197-205. doi: 10.1016/j.vaccine.2011.12.115. Epub 2012 Jan 20.
2
Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.M蛋白保守区抗体对泰国北部人群A组链球菌分离株的杀菌活性。
BMC Microbiol. 2006 Aug 9;6:71. doi: 10.1186/1471-2180-6-71.
3
Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.由活的重组乳酸乳球菌制成的黏膜疫苗可保护小鼠免受化脓性链球菌的咽部感染。
Infect Immun. 2004 Jun;72(6):3444-50. doi: 10.1128/IAI.72.6.3444-3450.2004.
4
Structure-based design of broadly protective group a streptococcal M protein-based vaccines.基于结构设计的具有广泛保护性的A群链球菌M蛋白疫苗
Vaccine. 2017 Jan 3;35(1):19-26. doi: 10.1016/j.vaccine.2016.11.065. Epub 2016 Nov 24.
5
Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.用四表位脂质核心肽疫苗构建体进行免疫接种可诱导针对A组链球菌的广泛保护性免疫反应。
J Infect Dis. 2006 Jun 15;193(12):1666-76. doi: 10.1086/504266. Epub 2006 May 10.
6
Predicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate.基于重组C重复区域的化脓性链球菌候选疫苗的预测覆盖率和免疫安全性。
PLoS One. 2016 Jun 16;11(6):e0156639. doi: 10.1371/journal.pone.0156639. eCollection 2016.
7
Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.对两种A组链球菌候选疫苗进行的计算机模拟比较分析预测,它们可能具有相似的安全性。
Vaccine. 2007 May 4;25(18):3567-73. doi: 10.1016/j.vaccine.2007.01.079. Epub 2007 Jan 25.
8
Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.当作为重组融合蛋白表达时,构象表位的结构优化可提高抗原性。
Vaccine. 2009 Nov 12;27(48):6799-806. doi: 10.1016/j.vaccine.2009.08.049. Epub 2009 Sep 1.
9
Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.通过接种自佐剂脂质核心M蛋白肽预防A组链球菌感染。
Vaccine. 2005 Mar 18;23(17-18):2298-303. doi: 10.1016/j.vaccine.2005.01.041.
10
Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.朝着开发一种高纯度、广泛保护范围的合成A群链球菌疫苗的方向发展。
J Med Chem. 2004 Jul 29;47(16):4100-4. doi: 10.1021/jm040041w.

引用本文的文献

1
Cell-Penetrating Peptides-Based Liposomal Delivery System Enhanced Immunogenicity of Peptide-Based Vaccine against Group A Streptococcus.基于细胞穿透肽的脂质体递送系统增强了基于肽的A组链球菌疫苗的免疫原性。
Vaccines (Basel). 2021 May 12;9(5):499. doi: 10.3390/vaccines9050499.
2
Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus.抗A组链球菌肽疫苗及其递送系统研发的最新进展
Vaccines (Basel). 2019 Jul 1;7(3):58. doi: 10.3390/vaccines7030058.
3
Molecular Epidemiology, Ecology, and Evolution of Group A Streptococci.
A 组链球菌的分子流行病学、生态学和进化。
Microbiol Spectr. 2018 Sep;6(5). doi: 10.1128/microbiolspec.CPP3-0009-2018.
4
Predicting Promiscuous T Cell Epitopes for Designing a Vaccine Against Streptococcus pyogenes.预测用于设计针对酿脓链球菌疫苗的高变 T 细胞表位。
Appl Biochem Biotechnol. 2019 Jan;187(1):90-100. doi: 10.1007/s12010-018-2804-5. Epub 2018 Jun 11.
5
Predicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate.基于重组C重复区域的化脓性链球菌候选疫苗的预测覆盖率和免疫安全性。
PLoS One. 2016 Jun 16;11(6):e0156639. doi: 10.1371/journal.pone.0156639. eCollection 2016.
6
Modification of the classical Lancefield assay of group A streptococcal killing to reduce inter-donor variation.改良经典的A群链球菌杀菌兰斯菲尔德试验以减少供体间差异。
J Microbiol Methods. 2016 May;124:69-71. doi: 10.1016/j.mimet.2016.03.015. Epub 2016 Mar 24.
7
A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development.化脓性链球菌的系统功能分类,作为分子分型和疫苗开发的新工具。
J Infect Dis. 2014 Oct 15;210(8):1325-38. doi: 10.1093/infdis/jiu260. Epub 2014 May 5.
8
Disease manifestations and pathogenic mechanisms of Group A Streptococcus.A 组链球菌的疾病表现及致病机制
Clin Microbiol Rev. 2014 Apr;27(2):264-301. doi: 10.1128/CMR.00101-13.
9
Strategies in the development of vaccines to prevent infections with group A streptococcus.预防 A 组链球菌感染疫苗的研发策略。
Hum Vaccin Immunother. 2013 Nov;9(11):2393-7. doi: 10.4161/hv.25506. Epub 2013 Jun 28.
10
Staphylococcal and streptococcal superantigen exotoxins.葡萄球菌和链球菌超抗原外毒素。
Clin Microbiol Rev. 2013 Jul;26(3):422-47. doi: 10.1128/CMR.00104-12.